title: Terbinafine-induced subacute cutaneous lupus erythematosus.
abstract: Terbinafine is a synthetic oral allylamine that is used for systemic treatment of microscopy- or culture-proven dermatophyte infections of skin and nails. It is normally well-tolerated and side effects include transient gastrointestinal symptoms and skin reactions that can occur in up to 2.3% of treated patients. Subacute cutaneous lupus erythematosus (SCLE) is a skin reaction that has been reported secondary to use of a variety of drugs. The number of reports of SCLE with terbinafine is limited. We demonstrate 2 patients in one dermatology clinic who presented with a predisposing autoimmune diathesis within 3 months of each other.
authors.affiliation: Wilford Hall Medical Center, Lackland Air Force Base, Lackland AFB, TX 78236-9908, USA. chivnor@pol.net
authors.forename: Chad M
authors.initials: CM
authors.lastname: Hivnor
authors.forename: Matthew L
authors.initials: ML
authors.lastname: Hudkins
authors.forename: Bert
authors.initials: B
authors.lastname: Bonner
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003881:Dermatomycoses / Q000188:drug therapy; D005260:Female; D006099:Granuloma / Q000188:drug therapy; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced*; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000009:adverse effects*; D012871:Skin Diseases / Q000188:drug therapy; D000077291:Terbinafine
chemical_list: D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine